Arzerra, known chemically as ofatumumab, was being tested in patients with a type of blood cancer known as bulky fludarabine-refractory chronic lymphocytic leukemia, as required by European regulators for conditional approval of the medicine. The companies said they were unlikely to apply for marketing of approval for the drug to treat such patients, based on the results of the study.

READ FULL ARTICLE Curated publisher From Reuters